🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 27 of 55

  1. Ivonescimab

    Summit Therapeutics

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  2. Ivonescimab

    Summit Therapeutics

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  3. Ivonescimab

    Summit Therapeutics

    Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  4. Ivonescimab

    Summit Therapeutics

    Stomach Cancer Stage IV

    phase 2 small molecule active

    1 trial

  5. Ivonescimab

    Summit Therapeutics

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  6. Ivonescimab

    Summit Therapeutics

    Thymus Carcinoma

    phase 2 mab active

    1 trial

  7. Ivonescimab

    Summit Therapeutics

    Endometrial Cancer

    phase 2 small molecule active

    1 trial

  8. Ivonescimab

    Summit Therapeutics

    Metastatic Esophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. Ivonescimab

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  10. Ivonescimab

    Summit Therapeutics

    Leiomyosarcoma

    phase 2 small molecule active

    1 trial

  11. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Extensive Stage Lung Small Cell Cancer

    phase 2 small molecule active

    1 trial

  12. Ivonescimab 20 mg/kg

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  13. Ivonescimab combined with TP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. Ivosidenib combined with venetoclax and azacitidine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  15. Ixabepilone Injection

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  16. Ixazomib

    Takeda

    Triple-Negative Breast Cancer

    phase 2 small molecule terminated

    1 trial

  17. Ixazomib

    Takeda

    Mantle Cell Lymphoma

    phase 2 small molecule active

    2 trials

  18. Ixazomib

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial

  19. JAB-21822

    Lacuna Pharma Pty Ltd

    advanced solid tumors with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  20. JCAR017

    Celgene Europe Limited

    Lymphoma, Non-Hodgkin

    phase 2 small molecule completed

    1 trial

  21. JDQ443

    Novartis Pharmaceuticals

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 small molecule active

    1 trial

  22. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial

  23. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  24. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  25. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

  26. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    MMRd/MSI-H stage II-III endometrial cancer

    phase 2 small molecule active

    1 trial

  27. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Cervical cancer

    phase 2 small molecule active

    1 trial

  28. JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  29. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets

    The George Institute

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  30. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    Fondazione Telethon ETS

    HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  31. JIN-A02

    INTENSITY THERAPEUTICS, INC.

    EGFR Mutant Advanced Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. JMT108

    Shanghai University of Traditional Chinese Medicine

    Unresectable Locally Advanced or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  33. JNJ-17000139, JNJ-63723283, JNJ-63723283

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma of the Bladder

    phase 2 small molecule active

    1 trial

  34. JNJ-17000139, JNJ-63723283, JNJ-63723283

    Janssen-Cilag International N.V.

    Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder

    phase 2 small molecule active

    1 trial

  35. JNJ-42756493, JNJ-42756493, JNJ-42756493

    Janssen-Cilag International N.V.

    Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.

    phase 2 small molecule active

    1 trial

  36. JNJ-61186372, JNJ-63723283, JNJ-63723283

    Janssen-Cilag International N.V.

    Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  37. JNJ-63723283, JNJ-42756493, JNJ-42756493, JNJ-42756493

    Tour Hekla

    Muscle-invasive bladder cancer (MIBC)

    phase 2 small molecule active

    1 trial

  38. JNJ-73841937, JNJ-61186372

    Janssen-Cilag International N.V.

    Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  39. JNJ-73841937, Montelukast Sodium Tablets, Dexamethason 4 mg JENAPHARM®, Methotrexat-Ebewe, 10mg/ml, roztwór do wstrzykiwań, JNJ-61186372, Methotrexate

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  40. JNJ-73841937, PEMETREXED , JNJ-61186372, CARBOPLATIN

    Janssen-Cilag International N.V.

    Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  41. JS004

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  42. JZP598

    Jazz Pharmaceuticals Ireland Limited

    Patients with HER2-expressing solid tumors

    phase 2 small molecule active

    1 trial

  43. JZP598

    Ningbo Cancer Hospital

    Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, colorectal, head & neck or sarcoma) or HER2 mutant non-small cell lung cancer.

    phase 2 small molecule active

    1 trial

  44. JZP598, TRASTUZUMAB EMTANSINE, DOCETAXEL , TRASTUZUMAB , PACLITAXEL , PACLITAXEL ALBUMIN-BOUND, PERTUZUMAB , CARBOPLATIN , TRASTUZUMAB EMTANSINE

    Jazz Pharmaceuticals Ireland Limited

    HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  45. Jakavi 5 mg tablets, Venetoclax, Jakavi 20 mg tablets, Venetoclax, Jakavi 10 mg tablets, Venetoclax, Venetoclax, Venetoclax, Venetoclax, Jakavi 15 mg tablets

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  46. KB707

    Krystal Biotech Netherlands B.V.

    Lung Cancer, Non-small Cell

    phase 2 mab active

    1 trial

  47. KB707

    Krystal Biotech Netherlands B.V.

    Cancer

    phase 2 mab active

    1 trial

  48. KETOROLAC, PREGABALIN

    The George Institute

    Estrogen receptor-positive early breast cancer (ER + BC).

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.